Molecular phenotype predicts sensitivity of squamous cell carcinoma of the head and neck to epidermal growth factor receptor inhibition

Molecular Oncology

Volumn 7, Issue 3, 2013, Pages 359-368

  Young, Natalie R ^a   Liu, Jing ^a,b   Pierce, Carolyn ^a,c   Wei, Tai Fen ^a,d   Grushko, Tatyana ^a   Olopade, Olufunmilayo I ^a   Liu, Wanqing ^a,e   Shen, Christine ^a   Seiwert, Tanguy Y ^a   Cohen, Ezra E W ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c ADVOCATE ILLINOIS MASONIC MEDICAL CENTER   (United States)

^d New York Presbyterian Morgan Stanley Children's Hospital   (United States)

^e PURDUE UNIVERSITY   (United States)

Author keywords

AKT; EGFR; Gefitinib; Head and neck squamous cell carcinoma; PIK3CA mutations

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHATIDYLINOSITOL 4 PHOSPHATE 3 KINASE; PROTEIN KINASE B; SMALL INTERFERING RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CANCER RESISTANCE; CANCER SIZE; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SENSITIVITY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE DOSAGE; GENE EXPRESSION; GENE MUTATION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; IMMUNOBLOTTING; IN VITRO STUDY; MOUSE; NONHUMAN; PERIPHERAL LYMPHOCYTE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

MUS MUSCULUS;

EID: 84878111732     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2012.11.001     Document Type: Article

References (43)

1. Barch M.J., Knutsen T., Spurbeck J.L. The AGT Cytogenetics Laboratory Manual 1997, Lippincott-Raven Publishers, Philadelphia, p. 666. third ed.
2. Bonner J.A., Harari P.M., Giralt J., Azarnia N., Shin D.M., Cohen R.B., Jones C.U., Sur R., Raben D., Jassem J., Ove R., Kies M.S., Baselga J., Youssoufian H., Amellal N., Rowinsky E.K., Ang K.K. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 2006, 354:567-578.
3. Cardinali M., Pietraszkiewicz H., Ensley J.F., Robbins K.C. Tyrosine phosphorylation as a marker for aberrantly regulated growth-promoting pathways in cell lines derived from head and neck malignancies. Int. J. Cancer 1995, 61:98-103.
4. Chen L.F., Cohen E.E., Grandis J.R. New strategies in head and neck cancer: understanding resistance to epidermal growth factor receptor inhibitors. Clin. Cancer Res. 2010, 16:2489-2495.
5. Chung C.H., Ely K., McGavran L., Varella-Garcia M., Parker J., Parker N., Jarrett C., Carter J., Murphy B.A., Netterville J., Burkey B.B., Sinard R., Cmelak A., Levy S., Yarbrough W.G., Slebos R.J., Hirsch F.R. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J. Clin. Oncol. 2006, 24:4170-4176.
6. Chung C.H., Parker J., Levy S., Slebos R.J., Dicker A.P., Rodeck U. Gene expression profiles as markers of aggressive disease-EGFR as a factor. Int. J. Radiat. Oncol. Biol. Phys. 2007, 69:S102-S105.
7. Cohen E.E. Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. J. Clin. Oncol. 2006, 24:2659-2665.
8. Cohen E.E., Haraf D.J., Kunnavakkam R., Stenson K.M., Blair E.A., Brockstein B., Lester E.P., Salama J.K., Dekker A., Williams R., Witt M.E., Grushko T.A., Dignam J.J., Lingen M.W., Olopade O.I., Vokes E.E. Epidermal growth factor receptor inhibitor gefitinib added to chemoradiotherapy in locally advanced head and neck cancer. J. Clin. Oncol. 2010, 28:3336-3343.
9. Cohen E.E., Lingen M.W., Martin L.E., Harris P.L., Brannigan B.W., Haserlat S.M., Okimoto R.A., Sgroi D.C., Dahiya S., Muir B., Clark J.R., Rocco J.W., Vokes E.E., Haber D.A., Bell D.W. Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR. Clin. Cancer Res. 2005, 11:8105-8108.
10. De Roock, W., De Vriendt, V., Normanno, N., Ciardiello, F., Tejpar, S., KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol. 12, 594-603.
11. Fenic I., Steger K., Gruber C., Arens C., Woenckhaus J. Analysis of PIK3CA and Akt/protein kinase B in head and neck squamous cell carcinoma. Oncol. Rep. 2007, 18:253-259.
12. Freier K., Joos S., Flechtenmacher C., Devens F., Benner A., Bosch F.X., Lichter P., Hofele C. Tissue microarray analysis reveals site-specific prevalence of oncogene amplifications in head and neck squamous cell carcinoma. Cancer Res. 2003, 63:1179-1182.
13. Jimeno A., Kulesza P., Wheelhouse J., Chan A., Zhang X., Kincaid E., Chen R., Clark D.P., Forastiere A., Hidalgo M. Dual EGFR and mTOR targeting in squamous cell carcinoma models, and development of early markers of efficacy. Br. J. Cancer 2007, 96:952-959.
14. Jimeno A., Rubio-Viqueira B., Amador M.L., Oppenheimer D., Bouraoud N., Kulesza P., Sebastiani V., Maitra A., Hidalgo M. Epidermal growth factor receptor dynamics influences response to epidermal growth factor receptor targeted agents. Cancer Res. 2005, 65:3003-3010.
15. Kalish L.H., Kwong R.A., Cole I.E., Gallagher R.M., Sutherland R.L., Musgrove E.A. Deregulated cyclin D1 expression is associated with decreased efficacy of the selective epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in head and neck squamous cell carcinoma cell lines. Clin. Cancer Res. 2004, 10:7764-7774.
16. Keniry M., Parsons R. The role of PTEN signaling perturbations in cancer and in targeted therapy. Oncogene 2008, 27:5477-5485.
17. Koynova D.K., Tsenova V.S., Jankova R.S., Gurov P.B., Toncheva D.I. Tissue microarray analysis of EGFR and HER2 oncogene copy number alterations in squamous cell carcinoma of the larynx. J. Cancer Res. Clin. Oncol. 2005, 131:199-203.
18. Kozaki K., Imoto I., Pimkhaokham A., Hasegawa S., Tsuda H., Omura K., Inazawa J. PIK3CA mutation is an oncogenic aberration at advanced stages of oral squamous cell carcinoma. Cancer Sci. 2006, 97:1351-1358.
19. Kuo W.L., Liu J., Mauceri H., Vokes E.E., Weichselbaum R., Rosner M.R., Cohen E.E. Efficacy of the multi-kinase inhibitor enzastaurin is dependent on cellular signaling context. Mol. Cancer Ther. 2010, 9:2814-2824.
20. Leonard J.H., Kearsley J.H., Chenevix-Trench G., Hayward N.K. Analysis of gene amplification in head-and-neck squamous-cell carcinoma. Int. J. Cancer 1991, 48:511-515.
21. Licitra L., Mesia R., Rivera F., Remenar E., Hitt R., Erfan J., Rottey S., Kawecki A., Zabolotnyy D., Benasso M., Storkel S., Senger S., Stroh C., Vermorken J.B. Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study. Ann. Oncol. 2011, 22:1078-1087.
22. Lin C.J., Grandis J.R., Carey T.E., Gollin S.M., Whiteside T.L., Koch W.M., Ferris R.L., Lai S.Y. Head and neck squamous cell carcinoma cell lines: established models and rationale for selection. Head Neck 2007, 29:163-188.
23. Liu J., Kuo W.L., Seiwert T.Y., Lingen M., Ciaccio M.F., Jones R.B., Rosner M.R., Cohen E.E. Effect of complementary pathway blockade on efficacy of combination enzastaurin and rapamycin. Head Neck 2011, 33:1774-1782.
24. Liu W., Wu X., Zhang W., Montenegro R.C., Fackenthal D.L., Spitz J.A., Huff L.M., Innocenti F., Das S., Cook E.H., Cox N.J., Bates S.E., Ratain M.J. Relationship of EGFR mutations, expression, amplification, and polymorphisms to epidermal growth factor receptor inhibitors in the NCI60 cell lines. Clin. Cancer Res. 2007, 13:6788-6795.
25. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., Harris P.L., Haserlat S.M., Supko J.G., Haluska F.G., Louis D.N., Christiani D.C., Settleman J., Haber D.A. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2004, 350:2129-2139.
26. Nanda R. Targeting the human epidermal growth factor receptor 2 (HER2) in the treatment of breast cancer: recent advances and future directions. Rev. Recent Clin. Trial. 2007, 2:111-116.
27. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., Herman P., Kaye F.J., Lindeman N., Boggon T.J., Naoki K., Sasaki H., Fujii Y., Eck M.J., Sellers W.R., Johnson B.E., Meyerson M. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500.
28. Pectasides E., Rampias T., Kountourakis P., Sasaki C., Kowalski D., Fountzilas G., Zaramboukas T., Rimm D., Burtness B., Psyrri A. Comparative prognostic value of epidermal growth factor quantitative protein expression compared with FISH for head and neck squamous cell carcinoma. Clin. Cancer Res. 2011, 17:2947-2954.
29. Pedrero J.M., Carracedo D.G., Pinto C.M., Zapatero A.H., Rodrigo J.P., Nieto C.S., Gonzalez M.V. Frequent genetic and biochemical alterations of the PI 3-K/AKT/PTEN pathway in head and neck squamous cell carcinoma. Int. J. Cancer 2005, 114:242-248.
30. Perez C.A., Song H., Raez L.E., Agulnik M., Grushko T.A., Dekker A., Stenson K., Blair E.A., Olopade O.I., Seiwert T.Y., Vokes E.E., Cohen E.E.W. Phase II study of gefitinib adaptive dose escalation to skin toxicity in recurrent or metastatic squamous cell carcinoma of the head and neck. Oral Oncology 2012, 48:887-892.
31. Pisani P., Bray F., Parkin D.M. Estimates of the world-wide prevalence of cancer for 25 sites in the adult population. Int. J. Cancer 2002, 97:72-81.
32. Ramirez J., Mirkov S., Zhang W., Chen P., Das S., Liu W., Ratain M.J., Innocenti F. Hepatocyte nuclear factor-1 alpha is associated with UGT1A1, UGT1A9 and UGT2B7 mRNA expression in human liver. Pharmacogenomic. J. 2008, 8:152-161.
33. Ray M., Salgia R., Vokes E.E. The role of EGFR inhibition in the treatment of non-small cell lung cancer. Oncologist 2009, 14:1116-1130.
34. Rogers S.J., Box C., Chambers P., Barbachano Y., Nutting C.M., Rhys-Evans P., Workman P., Harrington K.J., Eccles S.A. Determinants of response to epidermal growth factor receptor tyrosine kinase inhibition in squamous cell carcinoma of the head and neck. J. Pathol. 2009, 218:122-130.
35. Sheu J.J., Hua C.H., Wan L., Lin Y.J., Lai M.T., Tseng H.C., Jinawath N., Tsai M.H., Chang N.W., Lin C.F., Lin C.C., Hsieh L.J., Wang T.L., Shih Ie M., Tsai F.J. Functional genomic analysis identified epidermal growth factor receptor activation as the most common genetic event in oral squamous cell carcinoma. Cancer Res. 2009, 69:2568-2576.
36. Siena S., Sartore-Bianchi A., Di Nicolantonio F., Balfour J., Bardelli A. Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J. Natl. Cancer Inst. 2009, 101:1308-1324.
37. Stewart J.S., Cohen E.E., Licitra L., Van Herpen C.M., Khorprasert C., Soulieres D., Vodvarka P., Rischin D., Garin A.M., Hirsch F.R., Varella-Garcia M., Ghiorghiu S., Hargreaves L., Armour A., Speake G., Swaisland A., Vokes E.E. Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]. J. Clin. Oncol. 2009, 27:1864-1871.
38. Stransky N., Egloff A.M., Tward A.D., Kostic A.D., Cibulskis K., Sivachenko A., Kryukov G.V., Lawrence M.S., Sougnez C., McKenna A., Shefler E., Ramos A.H., Stojanov P., Carter S.L., Voet D., Cortes M.L., Auclair D., Berger M.F., Saksena G., Guiducci C., Onofrio R.C., Parkin M., Romkes M., Weissfeld J.L., Seethala R.R., Wang L., Rangel-Escareno C., Fernandez-Lopez J.C., Hidalgo-Miranda A., Melendez-Zajgla J., Winckler W., Ardlie K., Gabriel S.B., Meyerson M., Lander E.S., Getz G., Golub T.R., Garraway L.A., Grandis J.R. The mutational landscape of head and neck squamous cell carcinoma. Science 2011, 333:1157-1160.
39. Temam S., Kawaguchi H., El-Naggar A.K., Jelinek J., Tang H., Liu D.D., Lang W., Issa J.P., Lee J.J., Mao L. Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. J. Clin. Oncol. 2007, 25:2164-2170.
40. Thomas S.M., Bhola N.E., Zhang Q., Contrucci S.C., Wentzel A.L., Freilino M.L., Gooding W.E., Siegfried J.M., Chan D.C., Grandis J.R. Cross-talk between G protein-coupled receptor and epidermal growth factor receptor signaling pathways contributes to growth and invasion of head and neck squamous cell carcinoma. Cancer Res. 2006, 66:11831-11839.
41. Vermorken J.B., Remenar E., van Herpen C., Gorlia T., Mesia R., Degardin M., Stewart J.S., Jelic S., Betka J., Preiss J.H., van den Weyngaert D., Awada A., Cupissol D., Kienzer H.R., Rey A., Desaunois I., Bernier J., Lefebvre J.L. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N. Engl. J. Med. 2007, 357:1695-1704.
42. Wheeler D.L., Dunn E.F., Harari P.M. Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat. Rev. Clin. Oncol. 2010, 7:493-507.
43. Wheeler D.L., Iida M., Kruser T.J., Nechrebecki M.M., Dunn E.F., Armstrong E.A., Huang S., Harari P.M. Epidermal growth factor receptor cooperates with Src family kinases in acquired resistance to cetuximab. Cancer Biol. Ther. 2009, 8:696-703.